A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

NCT00113412 | Unknown Phase 2

• 1 other identifier: SP01A-105-04
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 7

Brief Summary

One measurement of an HIV infected person's risk of progressing to AIDS is the number of viral particles of HIV in their blood (called a "viral load"). In a previous phase I/II study, SP01A was observed to significantly lower the amount of HIV in blood, improve quality of life (how well subject's felt), have a favorable safety profile (minimal side effects), and be well tolerated. Moreover, in in vitro testing SP01A: (1) demonstrated comparable or greater efficacy than currently approved anti-HIV drugs in preventing HIV virus replication; (2) was observed to have minimal toxic effect on human cells; and (3) demonstrated significant efficacy in preventing virus replication of HIV virus strains that resist currently approved anti-HIV treatments. Based on these results, SP01A demonstrates promise as a new and novel anti-HIV treatment. The goal of this study is to further look at the dose response, efficacy, and safety of SP01A as monotherapy, given as a capsule to be swallowed, in the treatment of HIV-infected subjects. The investigators want to see if SP01A will lower the amount of HIV in blood. Subjects will be assigned by chance to 1 of 4 groups. Neither the subject nor the study doctor or nurse will know which dose of the study drug the subject is taking or if the subject is receiving the placebo (a capsule that looks like the study drug but does not contain any active ingredient). At the end of the 10-day study, the subject will be offered testing of their virus for resistance to approved drugs (genotype) and transferred to their physician for continued treatment with FDA-approved antiretroviral therapies. If the subject experiences a side effect, which continues past the end of the study, they will be further monitored until the side effect goes away.

Conditions

HIV Infections

Keywords

HIV; Treatment Experienced

Outcome Measures

Primary Outcomes (1)

• The primary objective of this study is to assess the dose-response, efficacy, and safety of orally administered SP01A as monotherapy treatment in HIV-infected patients with evidence of resistance to currently available antiretroviral therapy.

Interventions

SP01A DRUG

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patient must be capable of giving informed consent. The principal investigator or study nurse will be responsible for obtaining written informed consent from potential patients prior to conducting any testing for the screening visit.
• \. Patient is HIV-positive and has treatment-experienced virologic failure or documented resistance. Treatment-experienced virologic failure is defined as patients meeting the following criteria; (1) previous experience with antiretroviral therapy from at least two of the approved antiretroviral classes (i.e. treatment with a nucleoside reverse transcriptase inhibitor, and/or non-nucleoside reverse transcriptase inhibitor, and/or protease inhibitor) for three to six months; (2) increasing HIV RNA after treatment had previously lowered viral load to low or undetectable levels; (3) increasing viremia (HIV RNA \> 5,000 copies/mL) in at least two viral load tests confirming their failing regimen. A patient does not need to currently be on therapy. A patient that is currently on a stable antiretroviral regimen that is successfully suppressing or maintaining viremia at low detectable levels (HIV RNA \< 5,000 copies/mL) is not eligible for entry into the study.
• Patient has been off all anti-viral medications, including any unapproved or experimental treatment for HIV and antiretrovirals, for at least 4 weeks prior to Study Day-1 (baseline). The patient may initiate this 4 week period after screening, if, in the judgment of the principal investigator, the patient qualifies for the study.
• Patient is at least 18 years of age and not older than 60 years of age.
• Patient is capable of adhering to the protocol.
• Patient has a CD4+ count \>50 cells/ml.
• Patient has a viral load of \> 5000 copies/ml.
• Patient has a Karnofsky score greater than or equal to 60.
• Female patients that are of childbearing potential: (1) have a negative urine pregnancy test at screening, and agree to use a condom and another form of contraception from the start of the study; or (2) are incapable of becoming pregnant.

You may not qualify if:

• Patients are ineligible to participate in the study if ANY of the following criteria are met.
• Patients with known or suspected allergy to procaine hydrochloride.
• Patients using sulfonamides (including Septra/Bactrim). Sulfonamides should not be used while on SP01A, because procaine will inactivate it. If a patient must be treated with Septra/Bactrim, that patient will be removed from the study.
• Patients with glaucoma using anti-cholinesterase inhibitors (Humorsol \[demecarium bromide\] echothiophate iodide, Floropryl \[isoflurophate\], Isopto-Eserine \[physostigmine salicylate\]). Anti-cholinesterase inhibitors should not be used while on SP01A, since anticholinesterases inhibit the breakdown of procaine hydrochloride.
• Patients with SGOT baseline value \>3 times upper limit.
• Patients with SGPT baseline value \>3 times upper limit.
• Patients with creatinine \>2.0 mg/ dl.
• Patients with absolute neutrophil count \<1,000 cells/mm3.
• Patients with platelets baseline value \<75,000 cells/µl.
• Patients that currently have any active opportunistic infection. Prophylaxis for Mycobacterium avium intracellulare (MAI), cytomegalovirus (CMV), Pneumocystis carinii pneumonia (PCP), or herpes is permitted (excluding treatment with Sulfonamides).
• Females that are pregnant or breast feeding.
• Female patients of childbearing age who cannot either use dual contraception or abstain from sexual intercourse during the clinical study.
• Patients with less than 6 months life expectancy.
• Patients with active hepatitis (viral or drug induced).
• Patients with cancer, except peripheral (dermal) Kaposi's sarcoma.

Sponsors & Collaborators

• Samaritan Pharmaceuticals, Inc: lead

Study Sites (7)

Therafirst Medical Centers

Fort Lauderdale, Florida, 33308, United States

Location

BioCollections Worldwide, Inc.

Miami, Florida, 33137, United States

Location

Orlando Immunology Center

Orlando, Florida, 32803, United States

Location

Infectious Disease Research Institute

Tampa, Florida, 33614, United States

Location

Anderson Medical Group

Pittsburgh, Pennsylvania, 15206, United States

Location

Tarant County Infectious Disease

Fort Worth, Texas, 76104, United States

Location

University of Texas Health Science Center

Houston, Texas, 77009, United States

Location

Related Publications (1)

• Xu J, Lecanu L, Han Z, Yao Z, Greeson J, Papadopoulos V. Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid levels. J Pharmacol Exp Ther. 2003 Dec;307(3):1148-57. doi: 10.1124/jpet.103.055178. Epub 2003 Oct 14.

  PMID: 14560037 BACKGROUND

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Erasto Saldi, MD

  Samaritan Pharmaceuticals, Inc

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 7, 2005
• First Posted: June 8, 2005
• Study Start: May 1, 2005
• Last Updated: March 22, 2006

Record last verified: 2006-03

Locations

US (7)